0.4527
Salarius Pharmaceuticals Inc Aktie (SLRX) Neueste Nachrichten
Salarius Pharmaceuticals To Implement 1-for-15 Reverse Stock Split - Nasdaq
Salarius Pharmaceuticals to implement 1-for-15 reverse stock split By Investing.com - Investing.com Australia
Salarius Pharmaceuticals announces 1-for-15 reverse stock split - MarketScreener
Salarius Pharmaceuticals Announces 1-for-15 Reverse Stock Split - GlobeNewswire
Salarius Pharmaceuticals Announces 1-For-15 Reverse Stock Split - TradingView
Cancer Drug Developer Salarius Launches Stock Consolidation to Meet Nasdaq Requirements - Stock Titan
What MACD and RSI say about Salarius Pharmaceuticals Inc.Rate Cut & Verified Momentum Watchlists - Newser
Is a relief rally coming for Salarius Pharmaceuticals Inc. holdersEarnings Recap Summary & AI Driven Stock Movement Reports - Newser
What analysts say about Salarius Pharmaceuticals Inc. stock outlookWeekly Trend Report & Safe Entry Point Identification - Newser
Salarius Pharmaceuticals Inc. stock prediction for this weekPortfolio Performance Summary & Smart Money Movement Tracker - Newser
Advanced analytics toolkit walkthrough for Salarius Pharmaceuticals Inc.Risk Management & Weekly High Conviction Ideas - Newser
Technical signs of recovery in Salarius Pharmaceuticals Inc.Weekly Loss Report & Risk Managed Investment Strategies - Newser
Using data filters to optimize entry into Salarius Pharmaceuticals Inc.Portfolio Growth Summary & Expert Approved Momentum Ideas - Newser
How Salarius Pharmaceuticals Inc. stock performs during market volatility2025 Macro Impact & Free Safe Capital Growth Stock Tips - Newser
Salarius Pharmaceuticals Q2 2023 Earnings Report | Financial OutlookNews and Statistics - IndexBox
Will Salarius Pharmaceuticals Inc. see short term momentumWeekly Trade Review & Trade Opportunity Analysis Reports - Newser
Salarius: Q2 Earnings Snapshot - New Haven Register
Why Salarius Pharmaceuticals Inc. is moving todayMarket Performance Summary & Proven Capital Preservation Tips - Newser
What’s next for Salarius Pharmaceuticals Inc. stock priceJuly 2025 Momentum & Weekly Breakout Stock Alerts - Newser
What’s next for Salarius Pharmaceuticals Inc. stock price [2025 Valuation Update]Stock Portfolio Risk Control - Newser
Market reaction to Salarius Pharmaceuticals Inc.’s recent news [Forecast Cut]Free Stepwise Trade Signal Implementation - Newser
Heatmap analysis for Salarius Pharmaceuticals Inc. and competitorsFree Optimized Watchlist With Daily Adjustments - Newser
Can Salarius Pharmaceuticals Inc. stock double in the next yearTop ROI Picks for Fast Gains - kangso.co.kr
Using flow based indicators on Salarius Pharmaceuticals Inc.Free Weekly Stock Opportunity Radar Scanner - Newser
How Efficient Is Salarius Pharmaceuticals Inc. at Controlling Operating CostsGrowth Summary Based on Market Positioning - Newser
Salarius Pharmaceuticals Inc (SLRX) Stock: A Comprehensive 52-Week Review - investchronicle.com
What makes Salarius Pharmaceuticals Inc. stock price move sharplyFree Consistent Income Focused Trade List - Newser
Salarius Pharmaceuticals Inc. Company’s Quarterly Earnings Growth: What the Numbers SayPattern Breakout Tracker with Screener Tools - Newser
Market reaction to Salarius Pharmaceuticals Inc.’s recent newsLong-Term Stock Growth Forecast Insights - Newser
Reversal indicators forming on Salarius Pharmaceuticals Inc. stockMarket Opportunity Tracker for Swing Traders - Newser
Signal strength of Salarius Pharmaceuticals Inc. stock in tech scannersSwing Trade Watchlist with Entry Zones - Newser
Published on: 2025-08-09 21:32:39 - Newser
Competitive Positioning of Salarius Pharmaceuticals Inc.: Is It Leading or LaggingFundamental Analysis for Value Stock Selection - Newser
Visualizing Salarius Pharmaceuticals Inc. stock with heatmapsFree Low Capital High Return Stock Plans - Newser
Can volume confirm reversal in Rimini Street Inc.Short-Term Market Movement Forecast Report - Newser
Volatility clustering patterns for Salarius Pharmaceuticals Inc.Weekly Return Plan for Conservative Traders - Newser
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):